GCM
AZN icon

GKV Capital Management’s AstraZeneca AZN Stock Holding History

GKV Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Buy
11,245
+3,903
+53% +$734K 0.68% 46
2026
Q1 		$1.43M Buy
7,342
+2,842
+63% +$548K 0.54% 48
2025
Q4 		$827K Buy
+4,500
New +$789K 0.31% 58

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $2.92B AUM

GKV Capital Management's AZN Position: Q2 2026 in Review

GKV Capital Management increased its AstraZeneca (AZN) stake by 53% in Q2 2026, buying an estimated $734K and bringing the position to 11,245 shares worth $2.11M. The position accounts for 0.68% of the portfolio, ranked #46.

GKV Capital Management first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 688 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • GKV Capital Management held 11,245 shares of AstraZeneca worth $2.11M as of Q2 2026.
  • GKV Capital Management bought 3,903 AstraZeneca shares in Q2 2026, an estimated $734K.
  • AstraZeneca made up 0.68% of GKV Capital Management's portfolio in Q2 2026, its #46 holding.
  • GKV Capital Management first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • 688 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on GKV Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.